A Multicenter, Open-Label, Phase Ib/III Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CAN017 in Combination with Chemotherapy as the Second Line Treatment for Patients with Locally Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCC)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Aug 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AV 203 (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors CANbridge Pharmaceuticals

Most Recent Events

26 Aug 2019 According to the CANbridge Pharmaceuticals website, the company was formerly called as CANbridge Life Sciences.
09 May 2019 According to an AVEO Oncology media release, the company is planning to initiate trials in 2019.
14 Aug 2018 According to a CANbridge Life Sciences media release, the company plans to commence this trial in 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight